[177Lu]Lu-PSMA放射性配体治疗用于未接受系统治疗的转移性激素敏感性前列腺癌的回顾性研究
该回顾性研究纳入24例未接受过系统激素治疗或化疗的转移性激素敏感性前列腺癌(mHSPC)患者,评估[177Lu]Lu-PSMA放射性配体治疗的疗效与安全性。末次周期后1个月中位PSA从6.4 ng/mL显著降至2.3 ng/mL(p=0.002),15/24例(62.5%)达到PSA下降≥50%。基线总肿瘤体积(TTV)、骨转移 presence 和年龄<66.3岁是无ADT生存和无任何治疗生存的显著预测因素。
要点
- 未接受系统治疗的mHSPC患者中,[177Lu]Lu-PSMA-RLT后62.5%达到PSA下降≥50%。
- PSA下降≥50%者中位PSA-PFS为24.6个月,下降<50%者为5.2个月(p<0.0001)。
- 基线TTV、骨转移和年龄<66.3岁与更短的无ADT生存和无任何治疗生存相关。
核心结论
- 在未接受系统治疗的mHSPC患者中,[177Lu]Lu-PSMA-RLT展现强烈PSA下降、延长前列腺癌无进展期且耐受性良好。
- 基线TTV和转移范围是无ADT生存和无任何治疗生存的独立预测因素。
- PSMA PET来源的SUV参数在应答者与非应答者间无差异,提示初治mHSPC肿瘤生物学更均一。
研究设计与样本
- 回顾性分析纳入2015年9月至2025年2月期间接受[177Lu]Lu-PSMA-RLT、无既往系统激素治疗或化疗的mHSPC患者。
- 主要结局为末次周期后1个月PSA应答和PSA无进展生存(PFS),并监测血液学和生化指标评估毒性。
- 收集基线PSMA PET参数(SUVmax、平均SUV、峰值SUV、总肿瘤体积TTV),行单因素和多因素分析及Kaplan-Meier生存分析。
主要发现
- 共识别24例患者,中位PSA从基线6.4 ng/mL(范围0.49–3149)降至末次[177Lu]Lu-PSMA-RLT周期后1个月2.3 ng/mL(范围0.00–1731),p=0.002。
- 所有患者接受≥3个周期[177Lu]Lu-PSMA-RLT;15/24例(62.5%)达到PSA下降≥50%,其中10例(41.7%)下降≥80%。
- PSA下降≥50%者中位PSA-PFS为24.6个月,下降<50%者为5.2个月(p<0.0001)。
- Kaplan-Meier分析中,基线TTV、骨转移 presence 和年龄<66.3岁是更短无ADT生存和无任何治疗生存的显著预测因素(均p<0.05)。
- 基线转移灶SUV值在区分应答者与非应答者方面无预测价值;无严重治疗相关不良事件,1例(4.2%)在开始[177Lu]Lu-PSMA-RLT后10.3个月死亡。
关键数值与推荐
- PSA应答定义为末次周期后1个月PSA下降≥50%或≥80%。
- 中位PSA-PFS在PSA下降≥50%组为24.6个月,在下降<50%组为5.2个月(p<0.0001)。
- 基线TTV、骨转移和年龄<66.3岁与更短无ADT生存和无任何治疗生存显著相关(均p<0.05)。
临床怎么用
- 对于未接受系统治疗的mHSPC患者,[177Lu]Lu-PSMA-RLT可作为潜在治疗选择,需关注PSA应答深度。
- 基线TTV、骨转移状态和年龄可用于风险分层,辅助预测无ADT生存和无任何治疗生存。
- 治疗期间需监测血液学和生化指标评估毒性,该研究中未观察到严重治疗相关不良事件。
局限性
- 回顾性设计且样本量仅24例,结果需前瞻性研究验证。
- 研究未定义[177Lu]Lu-PSMA-RLT在该 setting 的临床获益和应答预测因素,需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lutetium-177-labelled radioligand therapy targeting prostate-specific membrane antigen ([¹⁷⁷Lu]Lu-PSMA-RLT) is an established third-line treatment for metastatic castration-resistant prostate cancer (mCRPC). We evaluated the therapeutic effectiveness of [¹⁷⁷Lu]Lu-PSMA-RLT in systemic therapy-naïve patients with metastatic hormone-sensitive prostate cancer (mHSPC). PATIENTS AND METHODS: This retrospective analysis included mHSPC patients without prior systemic hormone therapy or chemotherapy who received [¹⁷⁷Lu]Lu-PSMA-RLT between September 2015 and February 2025. The primary outcomes were prostate-specific antigen (PSA) response one month after the final cycle and PSA progression-free survival (PFS). Hematological and biochemical laboratory parameters were monitored to assess toxicity. Baseline PSMA PET imaging parameters (maximum standardized uptake value (SUVmax), mean SUV, peak SUV, and total tumor volume (TTV)) were collected. Uni- and multivariable analyses, together with Kaplan-Meier survival analysis, were performed to identify predictors of PSA-PFS, androgen deprivation therapy (ADT)-free survival, and any-therapy-free survival. RESULTS: Twenty-four patients were identified. Median PSA declined significantly from 6.4 ng/mL (range 0.49–3149) at baseline to 2.3 ng/mL (range 0.00-1731) one month after last [¹⁷⁷Lu]Lu-PSMA-RLT cycle (p = 0.002). All patients received ≥ 3 cycles of [177Lu]Lu-PSMA-RLT. Overall, 15 of 24 patients (62.5%) achieved a PSA decline ≥ 50%, including 10 patients (41.7%) with a decline ≥ 80%. Median PSA-PFS was 24.6 months in patients with a PSA decline ≥ 50%, versus 5.2 months in those with a decline < 50% (p < 0.0001). In the Kaplan-Meier analysis, baseline TTV, the presence of bone metastases, and age < 66.3 years were significant predictors of shorter ADT-free and any-therapy-free survival (all p < 0.05). In contrast, baseline SUV-values of metastatic lesions showed no predictive value in distinguishing responders from non-responders. No severe treatment-related adverse events occured. One patient (4.2%) died 10.3 months after initiation of [¹⁷⁷Lu]Lu-PSMA-RLT. CONCLUSION: This study evaluated [¹⁷⁷Lu]Lu-PSMA-RLT in early-stage PCa, demonstrating strong PSA decline, prolonged PCa progression-free period, and good tolerability. Baseline TTV and metastatic extent were independent predictors of ADT-free and any-therapy-free survival. The absence of differences in PSMA PET-derived SUV-parameters between responders and non-responders suggests a more homogeneous tumor biology in treatment-naïve mHSPC patients. Prospective studies are needed to define the clinical benefit and predictors of response to [¹⁷⁷Lu]Lu-PSMA-RLT in this setting.
引用
- Langrate IK, Ofner H, Kretschmer-Chott E, et al. [177Lu]Lu-PSMA radioligand therapy in systemic therapy-naïve metastatic hormone-sensitive prostate cancer patients: a retrospective study. Eur J Nucl Med Mol Imaging. 2026. PMID: 41680477. doi:10.1007/s00259-026-07802-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。